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Abstract The study was designed to evaluate the long-
term efficacy and safety of the 28-day prolonged-release
Autogel formulation of the somatostatin analogue lanreo-
tide (Lan-Autogel) in unselected patients with acromegaly.
The study comprised four phases: washout; a double-blind
comparison with placebo, at a single randomized dose (60,
90 or 120 mg) of Lan-Autogel; a single-blind, fixed-dose
phase for four injections (placebo group was re-allocated to
active treatment); and eight injections with doses tailored
according to biochemical response. Serum samples were
assessed for growth hormone (GH) and insulin-like growth
factor-1 (IGF-1) levels, at weeks 4, 13, 14, 15, 16, 32 and
52. 108 patients were enrolled and 99 completed 52 weeks’
treatment. Four weeks after the first injection, serum GH
levels decreased by[50% from baseline in 63% of patients
receiving Lan-Autogel compared with 0% receiving pla-
cebo (P \ 0.001). After four injections, 72% of patients
had a[50% reduction in GH levels; 49% patients achieved
GH levels B 2.5 ng/ml; 54% had normalized IGF-1; and
38% achieved the combined criterion of GH level
B 2.5 ng/ml and normalized IGF-1. The corresponding
proportions by week 52 were 82, 54, 59 and 43%,
respectively. In patients not requiring dose escalation to
120 mg, 85% achieved biochemical control (combined
criterion). Treatment was well tolerated by all patients. In
conclusion, Lan-Autogel was effective in controlling GH
and IGF-1 hypersecretion in patients with acromegaly and
showed a rapid onset of action.
Keywords Growth hormone 
Insulin-like growth factor-1  Somatostatin analogue 
Acromegaly  Lanreotide Autogel
Introduction
Acromegaly is a rare disease, with an average annual
incidence of approximately 3 per million and a prevalence
of approximately 60 per million. It is caused by an over-
production of growth hormone (GH) from a GH-secreting
pituitary adenoma. Acromegaly can be associated with a
variety of clinical features, and is usually characterized by
an insidious progression of dysmorphic skeletal and soft-
tissue growth, severe sweating, headaches, arthritis and, in
some patients, visual field loss [1]. Impaired cardiac and
respiratory functions are the most serious features of the
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disease, and these result in morbidity and mortality more
than double the rate of the general population [2–5]. Bio-
chemical control of the disease is primarily achieved through
surgical removal of the tumour. Radiotherapy can also be
used in some patients with recurrent or persistent tumours
[1]. In patients where these treatments are inappropriate, or
have proven to be unsuccessful, somatostatin analogues are
the recommended medical therapy [6, 7]. Indeed, treatment
with somatostatin analogues is increasingly considered as a
primary medical intervention in selected patients.
The somatostatin analogue lanreotide (Somatuline,
Ipsen) has demonstrated efficacy in the medical manage-
ment of acromegaly [8–11]. Somatuline Autogel (Lan-
Autogel) (marketed as Somatuline Depot in the US) is a
prolonged-release, supersaturated formulation of lanreo-
tide, which is available in sterile, ready-to-use syringes.
Lan-Autogel has good efficacy in the management of
acromegaly [12], including in long-term treatment [13–15],
and has a similar efficacy and safety profile to octreotide
[16, 17]. This somatostatin analogue formulation has also
simplified treatment by increasing the dosing interval,
potentially improving patient compliance and providing the
possibility of patient self-administration [18]. After deep
subcutaneous injection, the controlled release of lanreotide
maintains therapeutic levels beyond the 28-day dosing
period [19–21]. In this study (NCT number 00234572), the
efficacy and safety of a single dose of Lan-Autogel was
compared with placebo in a large international cohort of
patients with acromegaly. Furthermore, the study aimed to
confirm the long-term efficacy and safety of Lan-Autogel.
Methods
Patients
All patients were required to be at least 18 years old and
have active acromegaly. Patients who had never received a
somatostatin analogue (‘Naive’) or a dopamine agonist, or
had stopped taking this medication more than 3 months
before (‘Not Treated within 3 months’), were eligible if
their mean serum GH level was [5 ng/ml at screening.
Patients who were receiving a somatostatin analogue or a
dopamine agonist immediately prior to the study (‘Previ-
ously Treated’) underwent treatment washout until their
mean GH was [3 ng/ml, and had increased by at least
100% from screening values. The duration of washout
depended on the dosing interval of the previous drug: GH
and insulin-like growth factor-1 (IGF-1) levels were
assessed after two dosing intervals had elapsed since the
last injection. If patients still did not meet the inclusion
criteria, a second assessment was allowed 14–42 days later.
Patients were excluded if they had received radiotherapy
for acromegaly within 3 years or pituitary surgery within
3 months prior to screening, or anticipated requiring such
treatment during the study period. The use of Lan-Autogel
or a GH receptor antagonist at any time before the study,
were also exclusion criteria, as were pregnancy, breast-
feeding, or hepatic or renal impairment. Somatostatin
analogues (other than Lan-Autogel), dopamine agonists or
cyclosporine (due to the risk of reduced absorption when
co-administered with Lan-Autogel) were not permitted
during the study. The study was conducted in accordance
with the ethical principles stated in the Declaration of
Helsinki and with the laws and regulations of the countries
in which the research was conducted, whichever afforded
the greater protection to the individual. The investigators
adhered to the provisions set out in Good Clinical Practice
Guidelines.
Study design
Lan-Autogel was administered every 28 days by deep
subcutaneous injection for 13 injections (Fig. 1). The study
was conducted in four phases: the first was a washout phase
for previously treated patients, followed by a double-blind
phase, in which patients were randomized to one injection
of Lan-Autogel 60, 90 or 120 mg or placebo. In the fol-
lowing single-blind phase, patients received three further
injections at the same dose, and the placebo group was re-
allocated to Lan-Autogel 60, 90 or 120 mg. In the final,
open-label phase, doses could be titrated according to bio-
chemical response, as assessed 28 days after the fifth and
ninth injections (Fig. 1). At each titration step, the dose
could increase or decrease by only one dose level (30 mg)
and, once increased, the dose could not subsequently be
reduced.
Efficacy and safety assessments
Mean GH levels were determined from a series of seven
serum samples obtained at 30-min intervals at screening and
before each injection at weeks 4, 13, 14, 15, 16, 32 and 52,
or at the time of early withdrawal. A single serum sample
was obtained for the assessment of IGF-1 levels at the same
visits. Both GH and IGF-1 concentrations were measured
using Nichols Advantage Chemiluminescence assays
(Nichols Institute Diagnostics, CA, USA) at a single center.
The limits of detection and quantitation of the GH assay
were 0.01 and 0.15 ng/ml, respectively, intra-assay coeffi-
cient of variation was 2.6–7.9%, and inter-assay coefficient
of variation was 4.7–6.6%. For the IGF-1 assay, the limits
of detection and quantitation were 0.8 and 2 nmol/l,
respectively, the intra-assay variability was 4.9–7.9% and
the inter-assay variability was 5.0–8.7%. Serum samples
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from weeks 0, 4, 16, 36 and 52 were assessed for non-
specific binding (NSB) to lanreotide, and those which
showed [30% NSB were assessed for the presence of
antibodies against lanreotide. This was achieved by com-
paring the displacement obtained with lanreotide, octreotide
and somatostatins 14 and 28. Acromegaly symptoms were
assessed by the investigator during screening and at weeks
0, 4, 16, 32 and 52; standard biochemistry and haematology
assessments, physical examinations and electrocardiograms
(ECGs) were made at weeks 0, 4 16 and 52. Echocardiog-
raphy and gall-bladder ultrasound were performed at weeks
0, 16 and 52. A retrospective centralized analysis of ECG
and echocardiography data was conducted and the data
reviewed by a cardiologist. Adverse events were recorded at
each study visit.
Statistical analysis
The primary efficacy endpoint was the proportion of
patients with a [50% reduction in mean GH levels from
baseline to week 4. Each Lan-Autogel dose-group was
compared with placebo, as was the pooled Lan-Autogel
group (Lan-Autogel All). An exploratory analysis of the
primary efficacy endpoint was performed, stratified by
geographic region (USA and Europe plus Hong Kong)
using the Cochran-Mantel-Haenszel test (for the treatment
effect) and the Breslow-Day test (for the region by treat-
ment interaction). Secondary efficacy endpoints included
the effect of repeated Lan-Autogel injections on GH and
IGF-1 levels at specific time points: the proportions of
patients with [50% reduction in GH from baseline,
GH B 2.5 ng/ml, or normalized IGF-1 or both normalized
IGF-1 and GH B 2.5 ng/ml. The assessment of acromegaly
symptoms between baseline and weeks 4, 16, 32 and 52, or
the end of the study, was also an endpoint.
The analysis of categorical efficacy data was performed
using the Cochran-Mantel-Haenszel test, with the use of
the Mantel-Haenszel or the logit estimation of the odds
ratios, using region as a stratification variable. Changes in
continuous efficacy variables from baseline were analyzed
by ANOVA, using the baseline value as a covariate. The
primary efficacy endpoint was adjusted for multiple
comparisons using Fisher’s exact test with permutation
re-sampling. The intention-to-treat population was the
primary population for all efficacy analyses. Post hoc
analyses were performed to calculate treatment response
(percentage of patients with GH B 2.5 ng/ml; percentage
of patients with normalized IGF-1 and percentage of
patients meeting both of these criteria) by the following
baseline characteristics: sex, age, race, severity of acro-
megaly, previous drug treatment, history of radiotherapy
and surgery. These were calculated as mean percentage of
patients and 95% confidence intervals (CI).
Fig. 1 Study design showing the dose-titration schema. Dose-titration was based on serum levels of growth hormone (GH; ng/ml) and whether
insulin-like growth factor-1 (IGF-1) levels were in the age-adjusted normalized range (N);
A = GH [ 2.5 or GH B 2.5 ? IGF-1 [ N;
B = GH B 2.5 ? IGF-1 B N;
C = 1 \ GH B 2.5 ? IGF-1 B N;
D = GH B 1 ? IGF-1 B N;
E = GH [ 1 or GH B 1 ? IGF-1 [ N.
*Only if 60 mg originally
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Results
Patients
Patients were recruited at 30 centers in eight countries
across the USA, Europe and Hong Kong (Appendix). A
total of 220 patients were screened and 111 randomized
(Fig. 2). Study drug was received by 108 patients in the
double-blind phase; 50% were classified as Naive (n = 15)
or Not Treated within 3 months (n = 39), and 50% as
Previously Treated (n = 54). Of these, 107 patients con-
tinued to the single-blind phase (one patient withdrew
because of an adverse event ongoing from screening); 105
patients completed the double-blind phase and entered the
open-label dose-titration phase (two withdrawals were
caused by adverse events not related to treatment). The
study was completed by 99 patients (four patients withdrew
during the open-label phase because of a lack of efficacy
and two because of adverse events [growth of a pre-
existing meningioma in one patient and albuminuria, dia-
betic nephropathy and peripheral oedema in the other]). At
the end of the single-blind phase, the final dose of Lan-
Autogel was 60 mg for 34 patients, 90 mg for 36 patients
and 120 mg for 37 patients; the number of patients on each
dose at the end of the open-label phase was 21, 15 and 69,
respectively.
Baseline characteristics and pre-treatment status were
similar among dose groups (Table 1), except that
Fig. 2 Patient flow through the
study
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proportionally more Naive and Not Treated within
3 months patients were randomized to the 60 mg group
than the other dosing groups.
First injection
Four weeks after the first injection, more patients showed a
[50% reduction in GH level with Lan-Autogel than with
placebo (63, 52, 44, 90 and 0% of patients for Lan-Autogel
All, 60, 90, 120 mg and placebo, respectively). All dif-
ferences between the lanreotide groups and placebo were
statistically significant (P \ 0.001). No patients had GH
levels B 2.5 ng/ml at baseline (before the start of the
double-blind period). Four weeks after the first injection,
however, 34% (28/83) of patients in the Lan-Autogel All
group had this level of GH control, compared with none (0/
25) in the placebo group (P \ 0.001). Ten percent (8/83) of
the patients receiving Lan-Autogel had normal IGF-1 lev-
els at baseline, and the proportion increased to 25% (21/83)
after one injection; 8% (2/25) of the placebo group had
normal IGF-1 levels at baseline, which decreased to 4% (1/
25) 4 weeks after the first injection (P \ 0.05 vs. Lan-
Autogel All group). The combined criterion of GH lev-
els B 2.5 ng/ml and normalized IGF-1 levels was met by
16% (13/83) of patients in the Lan-Autogel All group and
0% in the placebo group, 4 weeks after the first injection.
Overall, mean (SD) GH concentrations declined from 20.3
(30.0) to 8.1 (13.5) ng/ml at week 4 and mean (SD) IGF-1
concentrations from 744 (236) to 532 (262) ng/ml in the
Lan-Autogel All group. These reductions were statistically
significant compared with the placebo group (mean GH
increased from 18.2 to 22.5 ng/ml, and mean IGF-1
increased from 702 to 733 ng/ml; P \ 0.001 vs. Lan-
Autogel groups). Analysis by geographical region showed
a similar response to treatment for patients from the USA
and those from Europe/Hong Kong.
Fixed-dose phase
After a further three injections of Lan-Autogel in the fixed-
dose phase, control of GH and IGF-1 levels continued to
improve. At week 16, 72% of patients had a[50% reduction
in GH levels from baseline, 49% had GH levels B 2.5 ng/ml
and 54% had normalized IGF-1 levels in the Lan-Autogel All
group (Fig. 3a). An indication of dose responsiveness was
apparent for[50% reduction in GH levels: a slightly higher
proportion showed a response in the 120 mg Lan-Autogel
group compared with the 90 and 60 mg groups but the dif-
ference was not statistically significant (P = 0.056 for 120
vs. 90 mg and P = 0.116 for 120 vs. 60 mg). Overall, mean
GH levels decreased by 62.3% (SD 36.6%; median reduction
was 75.5%) from baseline to week 16 with Lan-Autogel
Table 1 Baseline characteristics
Characteristic Lanreotide Autogel dose Placebo
(n = 25)
All patients
(n = 108)
60 mg
(n = 27)
90 mg
(n = 27)
120 mg
(n = 29)
Age (years), mean (SD) 52.2 (16.6) 54.5 (14.2) 55.6 (12.1) 51.4 (12.7) 53.5 (13.9)
Weight (kg), mean (SD) 80.1 (15.7) 81.5 (14.1) 87.1 (19.7) 86.4 (16.6) 83.8 (16.7)
Women, number (%) 14 (52) 18 (67) 13 (45) 12 (48) 57 (53)
Race, number (%)
Caucasian 22 (81) 24 (89) 25 (86) 20 (80) 91 (84)
Asian 2 (7) 2 (7) 3 (10) 4 (16) 11 (10)
Black 1 (4) 1 (4) 1 (3) 1 (4) 4 (4)
American Hispanic 2 (7) 0 0 0 2 (2)
Serum GH (ng/ml), mean (SD) 24.6 (45.6) 17.4 (17.5) 19.0 (19.8) 18.2 (27.3) 19.8 (29.3)
Serum IGF-1 (ng/ml), mean (SD) 710 (270) 728 (234) 791 (202) 702 (254) 735 (240)
Time since diagnosis (years), mean (SD) 5.5 (9.0) 6.4 (9.6) 7.4 (7.5) 6.5 (6.7) 6.5 (8.2)
Previous acromegaly surgery, number (%) 15 (56) 15 (56) 15 (52) 14 (56) 59 (55)
Previous acromegaly radiotherapy, number (%) 3 (11) 4 (15) 2 (7) 3 (12) 12 (11)
Acromegaly treatment at screening, number (%)a
No treatment or treatment stopped C 3 months ago 18 (67) 13 (48) 13 (45) 10 (40) 54 (50)
Lanreotide 30 mg 5 (19) 6 (22) 5 (17) 5 (20) 21 (19)
Octreotide long-acting 4 (15) 6 (22) 9 (31) 8 (32) 27 (25)
Octreotide short-acting 0 2 (7) 1 (3) 1 (4) 4 (4)
Dopaminergic agonist 1 (4) 1 (4) 1 (3) 1 (4) 4 (4)
a Patients may have received more than one treatment
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treatment (P \ 0.001), and the highest dose produced sig-
nificantly greater reductions than the lowest dose (mean [SD]
for 60 mg 53.0% [42.2%] vs. 120 mg 72.1% [33.0%];
P = 0.022).
At week 16, mean IGF-1 levels decreased from baseline.
Similarly for IGF-1, there was an indication of dose
responsiveness with a significant difference between doses
for the 60 mg (mean [SD] reduction of 32% [38%]) vs. the
120 mg group (54% [19%]; P = 0.002). There was a
similar response to treatment after 16 weeks across the
different geographical regions.
Dose-titration phase
By week 52, 82% of all patients (Lan-Autogel All) had a
mean decrease in serum GH levels of[50% from baseline
and 54% had mean GH levels B 2.5 ng/ml; 59% of
patients had normalized IGF-1 levels, and 43% had both
GH levels B 2.5 ng/ml and normalized IGF-1 levels
(Fig. 3b). GH and IGF-1 levels were significantly reduced
from baseline at week 52, with mean (SD) reductions of
67.1% (32.0%; P \ 0.001) and 48.9% (28.6%), respec-
tively (P \ 0.001; Fig. 4). According to the dosing
scheme, patients who were less responsive were given
higher doses; mean GH and IGF-1 levels were higher and
the proportion of patients with GH B 2.5 ng/ml and nor-
malized IGF-1 was lower in the 120 mg group than the
60 mg group. In patients not requiring dose escalation to
120 mg, 85% (29 of 34 patients) achieved biochemical
control (normalized IGF-1 levels and GH \ 2.5 ng/ml).
Subset analyses
At week 16 (the end of the fixed-dose phases), the pro-
portions of patients who were Naive or Not Treated within
3 months and Previously Treated in each dose group were
reasonably balanced, despite not having been stratified for
prior treatment. By week 52, most of the patients who were
Naive or Not Treated within 3 months (82%) were
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receiving the 120 mg dose, whereas 49% of Previously
Treated patients were receiving this dose. Most baseline
variables did not appear to affect response to treatment
(Table 2). However patients with less severe acromegaly at
baseline (GH \ 10 ng/ml) showed a better treatment
response (mean GH B 2.5 ng/ml) than those with more
severe disease (Table 2) and patients with prior pituitary
surgery also appeared to respond better.
Symptoms
Compared with baseline, acromegaly symptoms improved
or were stable in most patients. Between baseline and
week 16, perspiration was improved or stable in 94% of
patients, oedema of extremities in 93%, joint pain in 92%,
fatigue in 92%, headache in 94%, impotence in 94% and
oligomenorrhoea in 91%. By week 52, perspiration was
improved or stable in 93% of patients, oedema of
extremities in 94%, joint pain in 87%, fatigue in 90%,
headache in 88%, impotence in 89% and oligomenorrhoea
in 100%.
Safety
Across all three study phases, 98 of the 107 patients (92%)
who received Lan-Autogel, experienced at least one
adverse event. The most common adverse events were
gastrointestinal in nature and their incidence increased with
dose (Table 3). The majority of adverse events were rated
as mild to moderate; 30% (32/107) of patients experienced
severe adverse events. Severe events were reported in 15%
(7/46) patients during treatment with Lan-Autogel 60 mg,
17% (11/66) patients during treatment with Lan-Autogel
90 mg and 23% (17/74) patients with Lan-Autogel 120 mg
(note: any of the 32 patients experiencing a severe adverse
event could be counted more than once in these calcula-
tions if they experienced a severe adverse event on more
than one dose of Lan-Autogel). The most commonly
reported adverse events rated as severe were: abdominal
pain (7 patients, 7%), diarrhoea (6 patients, 6%), and
hypertension aggravated (3 patients, 3%). Other severe
adverse events were reported in no more than two patients.
Serious adverse events occurred in 17% (18/107) of
patients receiving Lan-Autogel, and in one patient (4%)
Table 2 Hormonal response to lanreotide (last value available) analysed by baseline demographic and disease characteristics
Mean GH B 2.5 ng/ml Normalized IGF-1 Mean GH B 2.5 ng/ml and
normalized IGF-1
% n/N 95% CI % n/N 95% CI % n/N 95% CI
Sex
Female 54.4 31/57 52.1, 79.2 59.6 34/57 45.8, 72.4 45.6 26/57 32.4, 59.3
Male 48.0 24/50 33.7, 62.6 56.0 28/50 41.3, 70.0 36.0 18/50 22.9, 50.8
Age (years)
\40 28.6 4/14 8.4, 58.1 64.3 9/14 35.1, 87.2 28.6 4/14 8.4, 58.1
40–64 55.2 37/67 42.6, 67.4 59.7 40/67 47.0, 71.5 44.8 30/67 32.6, 57.4
65–74 52.6 10/19 28.9, 75.6 47.4 9/19 24.4, 71.1 36.8 7/19 16.3, 61.6
C75 57.1 4/7 18.4, 90.1 57.1 4/7 18.4, 90.1 42.9 3/7 9.9, 81.6
Baseline mean GH (ng/ml)
\10 66.7 34/51 52.1, 79.2 66.7 34/51 52.1, 79.2 49.0 25/51 34.8, 63.4
C10 37.5 21/56 24.9, 51.5 50.0 28/56 36.3, 63.7 33.9 19/56 21.8, 47.8
Somatostatin analogue prior treatment
Naive 33.3 5/15 11.8, 61.6 40.0 6/15 16.3, 67.7 20.0 3/15 4.3, 48.1
Not treated within 3 months 38.5 15/39 23.4, 55.4 48.7 19/39 32.4, 65.2 33.3 13/39 19.1, 50.2
Previously treated 68.6 35/51 54.1, 80.9 70.6 36/51 56.2, 82.5 54.9 28/51 40.3, 68.9
Not known 0.0 0/2 0.0, 84.2 50.0 1/2 1.3, 98.7 0.0 0/2 0.0, 84.2
Prior radiotherapy
Yes 41.7 5/12 15.2, 72.3 66.7 8/12 34.9, 901 33.3 4/12 9.9, 65.1
No 52.6 50/95 42.1, 63.0 56.8 54/95 46.3, 67.0 42.1 40/95 32.0, 52.7
Prior pituitary surgery
Yes 59.3 35/59 45.7, 71.9 66.1 39/59 52.6, 77.9 50.8 30/59 37.5, 64.1
No 41.7 20/48 27.6, 56.8 47.9 23/48 33.3, 62.8 29.2 14/48 17.0, 44.1
Combined data Lan-Autogel All
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receiving placebo. Only one serious event, pancreatitis
associated with gall bladder lithiasis migration, was con-
sidered related to study treatment. No deaths occurred
during the study. One patient withdrew because of an
adverse event ongoing from screening, and three patients
receiving 90 mg and one receiving 120 mg of Lan-Autogel
withdrew because of adverse events (fracture, thyroid
carcinoma, diabetic nephropathy, growth of pre-existing
meningioma), but none was assessed as drug-related.
No clinically meaningful changes in haematology,
chemistry or vital signs were noted following single or
repeated injections of Lan-Autogel. There were no clini-
cally important changes in blood glucose levels and HbA1c
in any treatment group at weeks 4, 16 and 52. Gallstones
and/or sludge were already present in 30% (30/100) of
patients at baseline (19/100 with gallstones and 14/100 with
sludge; three patients had both). In total, 22 patients (26%)
whose baseline ultrasound was free of abnormalities had
newly identified gallstones or sludge by the end of the study.
For most patients (72% [73/101]), ECG assessments
were normal and remained normal during the study; 22
patients had abnormal ECGs both at baseline and at the end
of the study and five patients shifted from normal to
abnormal. Across all patients, heart rate decreased by a
mean (SD) of 8.4 (14.8) bpm and mean ECG intervals
changed accordingly. Although all changes from baseline
were statistically significant, they were within clinically
accepted normal limits. Echocardiography measurements
showed that no major modifications occurred during the
study, other than a decrease in left ventricular mass, which
paralleled the change in body size. Concordant with this,
mean (SD) left ventricular end-diastolic and -systolic vol-
umes decreased by 9.9 (20.3) and 5.4 (16.1) ml, respec-
tively. Valvular regurgitations were typical of patients with
acromegaly and did not show any clinically meaningful
changes over time.
The presence of putative antibodies to Lan-Autogel was
observed in one patient in two samples (at baseline and
after the first injection). However, no assessment of puta-
tive antibodies could be found in later samples; this patient
had normalized IGF-1 levels by week 16 and had no
allergic-type reaction. The only drug-related adverse event
reported for this patient was diarrhoea at week 15.
Discussion
This 52-week, four-phase study in a large international
cohort of unselected patients with acromegaly has shown a
sustained control of GH and IGF-1 levels with 28-day Lan-
Autogel treatment. The design of the trial allowed a dou-
ble-blind comparison with placebo for a single, randomized
dose of Lan-Autogel 60, 90 or 120 mg. These doses were
continued in the fixed-dose phase for a further four injec-
tions (with placebo-patients re-allocated) allowing inves-
tigation of dose-responsiveness. Doses were tailored
according to biochemical response in the open-label titra-
tion phase, which mimicked actual clinical practice, with
Table 3 Number of patients experiencing treatment-emergent adverse events during weeks 0–54, by dose at onset of the event
Patients experiencing adverse event at given dose [n (%)]
Lanreotide Autogel dose Total (n = 107)a
60 mg (n = 46)a 90 mg (n = 66)a 120 mg (n = 74)a
Any AE 33 (72) 47 (71) 67 (91) 98 (92)
Any gastrointestinal AE 16 (35) 28 (42) 46 (62) 72 (67)
Most commonly reported AEs
Diarrhoea 10 (22) 19 (29) 35 (47) 51 (48)
Cholelithiasis 8 (17) 9 (14) 18 (24) 32 (30)
Abdominal pain 5 (11) 9 (14) 11 (15) 23 (21)
Bradycardia 7 (15) 5 (8) 4 (5) 15 (14)
Arthralgia 3 (7) 8 (12) 4 (5) 14 (13)
Anaemia 3 (7) 6 (9) 4 (5) 13 (12)
Alopecia 5 (11) 3 (5) 7 (9) 13 (12)
Injection-site mass 2 (4) 2 (3) 8 (11) 11 (10)
Flatulence 2 (4) 3 (5) 7 (9) 11 (10)
Nausea 3 (7) 2 (3) 6 (8) 11 (10)
Data are number (%) of patients. AE, adverse event
a The number of patients in the ‘total’ column is the total number of patients in the study; the number of patients in the three other columns is the
number of patients who received the given dose of Lan-Autogel at any time during the study. Thus, a single patient could be included in more
than one column
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the exception that once doses were increased, they could
not then be reduced.
The primary efficacy outcome, a [50% reduction in
mean GH levels from baseline, was selected to show
clearly the different responses to Lan-Autogel and placebo,
4 weeks after a single injection. This reduction in GH
levels was achieved in 63% of patients receiving Lan-
Autogel but not in any patients receiving placebo. As
steady-state levels of lanreotide were achieved after 3–4
injections [20], the proportion of patients with mean
GH B 2.5 ng/ml increased, reaching 49% of all patients at
week 16 and 54% at week 52. IGF-1 control also improved:
59% of patients had age-adjusted normalized levels by
week 52 and 43% achieved control of both the GH and
IGF-1 parameters by week 52.
It is notable that patients who had previously received a
somatostatin analogue, or a dopaminergic agonist, had a
significantly enhanced response rate than patients who
were Naive or Not Treated within 3 months of the study.
At the end of the study, 69% of Previously Treated patients
had GH levels B 2.5 ng/ml. The corresponding proportion
was 38.5% for patients Not Treated within previous
3 months and 33% for truly drug-naive patients. A similar
effect was seen for normalized IGF-1 levels, the corre-
sponding values were 71, 49 and 40% at week 52,
respectively. This observation is readily explained if we
consider that patients who gained benefit from treatment
with somatostatin analogues were more likely to have
continued such therapy up to study entry, whereas those
who had previously not experienced a treatment response
were more likely to have discontinued therapy before the
study. The population of drug-naive patients would not be
biased in this way towards any treatment response.
Less severe acromegaly at baseline was easier to treat
than more severe disease, which was reflected in greater
treatment responses at endpoint. Not all studies of
somatostatin analogues are in agreement with this obser-
vation, for example, work by Cozzi et al. with octreotide
shows no relationship between response and baseline levels
of GH or IGF-1 [22, 23]. One limitation of this study was
the absence of adenoma size measurements that could have
provided information on tumor shrinkage.
In addition, prior pituitary surgery tended to predispose
patients to a better treatment response to Lan-Autogel, a
finding that has also been reported for the lanreotide
microparticle formulation [24]. There were too few patients
having previously undergone radiotherapy to confidently
assess its effect on response to lanreotide.
Natural variations in responsiveness to somatostatin
analogues among the population as a whole is well estab-
lished, and is thought to arise from differing expressions of
somatostatin receptor subtypes, notably receptors 2 and 5
[25, 26].
The efficacy of Lan-Autogel demonstrated in the total
population of the present study is comparable with results
previously published for octreotide [27]. Indeed, the effi-
cacy outcomes of the present study are almost identical to
those from the study of Cozzi et al. [22]. Twelve months’
treatment with octreotide long-acting repeatable (LAR),
achieved GH levels \ 2.5 ng/ml in 54% of patients and
normalized IGF-1 in 61%. This similarity in efficacy
between the two somatostatin analogues has been demon-
strated in many comparative studies [28–31]. A review
conducted in 2003 concluded that in unselected patients
octreotide LAR was more effective than slow release lan-
reotide for reducing GH and IGF-1 levels [32], but a recent
review of the literature reporting the efficacy of lanreotide
and octreotide LAR demonstrated that Lan-Autogel and
octreotide LAR were equivalent in both biological and
symptom control in patients with acromegaly [17]. The
recently updated guidelines on acromegaly management
also state that octreotide LAR and Lan-Autogel have
equivalent efficacy [33].
At the end of the fixed-dose phase, an indication of
dose-responsiveness was apparent. The decline in mean
GH and IGF-1 levels was greater, and the proportions of
patients achieving control tended to be higher, amongst the
group randomized to 120 mg than the lower dose groups.
This dose-responsiveness was reversed during the dose-
titration phase, as patients who responded less well to
treatment underwent dose titration to higher doses of Lan-
Autogel.
Treatment with Lan-Autogel was generally well toler-
ated and the incidence of adverse events was low. This is
reflected by the large proportion of patients who remained
in the study: 99 of 111 patients randomized to treatment
completed the study and there were no withdrawals as a
result of treatment-related adverse events. The most com-
mon adverse events were, as expected, gastrointestinal in
nature. As is seen with all somatostatin-analogue therapies,
there was an increase in the incidence of gall-bladder
lithiasis and sludge over the course of the study. However,
cardiac findings were unremarkable and all changes would
have been expected in this patient population. Adminis-
tration of Lan-Autogel by deep subcutaneous injection was
shown to have negligible immunogenic impact, with
putative antibodies against lanreotide detected in only one
patient.
In summary, Lan-Autogel was effective in controlling
GH and IGF-1 hypersecretion in patients with acromegaly
and showed a rapid onset of action. It was well tolerated
and the safety profile was as expected for a somatostatin
analogue. The results support the concept that the deep
subcutaneous route is both safe and effective compared
with deep intramuscular injections, and the 28-day dosing
regimen met with high patient compliance. These results
26 Pituitary (2010) 13:18–28
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further support the use of Lan-Autogel for the long-term
treatment of acromegaly.
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Appendix
The Global Study Group for Lanreotide Autogel in Acro-
megaly comprises the following investigators, who con-
ducted this study: S. Melmed (USA), A. Barkan (USA),
D. Cook (USA), D. Kleinberg (USA), L. Katznelson (USA),
M. Molitch (USA), P. Snyder (USA), P. Kim (USA), E. Ennis
(USA), M. Sharma (USA), G. Weryha (France), D. Dewailly
(France), P. Jaquet (France), A. Warnet (France), X. Bertagna
(France), H. Gerl (Germany), J. Schopohl (Germany),
K. Mann (Germany), P. Stewart (UK), P. Bouloux (UK),
R. Salvatori (USA), J. Marek (Czech Republic), J. Cap (Czech
Republic), J. Mertl (Czech Republic), W. de Herder (The
Netherlands), A. Arias (The Netherlands), K. Racz (Hungary),
M. Goth (Hungary), K. Lam (Hong Kong), P. Trainer (UK).
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